SpyGlass Pharma, Inc. SGP
37.16 USD +0.21 (+0.57%)
Nov 9, 2026, 1:29 PM EST
36.90 Day range 39.92
17.06 52-week range 39.92
- YTD
- +40.75%
- 1 year
- +40.75%
News
globenewswire.com SpyGlass Pharma to Participate in Upcoming Investor Conferences IRVINE, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma” or “Company”), a late-stage biopharmaceutical company, today announced that members of the…
benzinga.com HC Wainwright & Co. Reiterates Buy on SpyGlass Pharma, Maintains $37 Price Target HC Wainwright & Co. analyst Yi Chen reiterates SpyGlass Pharma (NASDAQ:SGP) with a Buy and maintains $37 price target.
benzinga.com SpyGlass Pharma Announces Trial Results From Bimatoprost Drug Pad-IOL System In Participants With Mild-To-Moderate Open Angle Glaucoma Reduces Mean IOP By 37% Across All Three Dose Cohorts; 86% Participants Remained Off All Topical IOP-Lowering Drops SpyGlass Pharma, Inc. (Nasdaq: SGP) ("SpyGlass Pharma" or "Company"), a late-stage biopharmaceutical company dedicated to transforming the treatment paradigm for patients living with chronic eye
benzinga.com HC Wainwright & Co. Reiterates Buy on SpyGlass Pharma, Maintains $37 Price Target HC Wainwright & Co. analyst Yi Chen reiterates SpyGlass Pharma (NASDAQ:SGP) with a Buy and maintains $37 price target.
benzinga.com SpyGlass Pharma Acquires Advanced Vision Science For ~$13M In Cash SpyGlass Pharma acquires 100% of the outstanding shares of AVS, a subsidiary of Santen Pharmaceutical Co., Ltd. (Santen), the existing manufacturer of SpyGlass Pharma’s intraocular lens (IOL)Secures…
benzinga.com This Aehr Test Systems Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday (CORRECTED) Wall Street analysts changed ratings for top names. Visit our analyst ratings page for details. SGP initiated with Outperform, $39 PT.
benzinga.com Raymond James Initiates Coverage On SpyGlass Pharma with Outperform Rating, Announces Price Target of $39 Raymond James analyst Christopher Raymond initiates coverage on SpyGlass Pharma (NASDAQ:SGP) with a Outperform rating and announces Price Target of $39.
benzinga.com SpyGlass Says AMA CPT Editorial Panel Approves New Add-On Category III CPT Code For Attachment, Insertion Of Intraocular Lens Prosthesis-Mounted Drug-Eluting Implant SpyGlass Pharma, Inc. (NASDAQ:SGP) (SpyGlass Pharma), a late-stage biopharmaceutical company, today announced that the American Medical Association's (AMA) CPT® (Current Procedural Terminology)…
benzinga.com SpyGlass Pharma Q1 EPS $(0.69) Misses $(0.42) Estimate SpyGlass Pharma (NASDAQ:SGP) reported quarterly losses of $(0.69) per share which missed the analyst consensus estimate of $(0.42) by 64.29 percent. This is a 82.58 percent increase over losses of…- benzinga.com SpyGlass Pharma Q4 EPS $(5.72) Down From $(4.58) YoY SpyGlass Pharma (NASDAQ:SGP) reported quarterly losses of $(5.72) per share. This is a 24.89 percent decrease over losses of $(4.58) per share from the same period last year.
benzinga.com HC Wainwright & Co. Initiates Coverage On SpyGlass Pharma with Buy Rating, Announces Price Target of $37 HC Wainwright & Co. analyst Yi Chen initiates coverage on SpyGlass Pharma (NASDAQ:SGP) with a Buy rating and announces Price Target of $37.- benzinga.com SpyGlass Pharma Announces Positive Topline 1/2 Trial Results For BIM-IOL Intracranial Pressure Treatment 12-month results from the Phase 1/2 trial evaluating its lead product candidate, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), for the treatment of elevated intraocular pressure (IOP) in…
benzinga.com This MongoDB Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday Wall Street analysts changed ratings on top companies. See full list at benzinga.com/analyst-stock-ratings. MDB outlook downgraded to Neutral.- benzinga.com Citigroup Initiates Coverage On SpyGlass Pharma with Buy Rating, Announces Price Target of $42 Citigroup analyst Yigal Nochomovitz initiates coverage on SpyGlass Pharma (NASDAQ:SGP) with a Buy rating and announces Price Target of $42.
- benzinga.com Leerink Partners Initiates Coverage On SpyGlass Pharma with Outperform Rating, Announces Price Target of $42 Leerink Partners analyst Marc Goodman initiates coverage on SpyGlass Pharma (NASDAQ:SGP) with a Outperform rating and announces Price Target of $42.
benzinga.com Jefferies Initiates Coverage On SpyGlass Pharma with Buy Rating, Announces Price Target of $62 Jefferies analyst Dennis Ding initiates coverage on SpyGlass Pharma (NASDAQ:SGP) with a Buy rating and announces Price Target of $62.
benzinga.com This Amylyx Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday Top Wall Street analysts changed outlook on top names. Check out analyst ratings page for all changes. AMLX, OFRM, AGMB, SGP initiated with positive outlook.- benzinga.com Stifel Initiates Coverage On SpyGlass Pharma with Buy Rating, Announces Price Target of $42 Stifel analyst Tom Stephan initiates coverage on SpyGlass Pharma (NASDAQ:SGP) with a Buy rating and announces Price Target of $42.
benzinga.com Spyglass Pharma, Inc To Start Trading Tomorrow - benzinga.com Assistant Secretary for International Finance Charles Collyns Written Testimony before the House Committee on Financial Services Subcommittee on International Monetary Policy and Trade
- benzinga.com UPDATE: ISI Group Initiates Coverage on NetApp at Buy, $48 PT
- benzinga.com Benzinga's Political Roundup
- benzinga.com Time Warner Director Buys $1 Million Worth Of Shares (TWX, SGP)
- benzinga.com The World's Largest M&A Deals in 2009 (PFE, WLA, GM, SGP, MRK)
- benzinga.com Priceline.com Added To The S&P 500, Replacing Schering-Plough
benzinga.com European Commission Approves Schering-Plough (SGP) and Centocor's Simponi Drug - benzinga.com US Court Rejects the Attempt by Schering-Plough's (SGP) to Repatriate $690M without Taxes
- benzinga.com SGP Reports Second Quarter 2009 Results VANCOUVER, BRITISH COLUMBIA--(Marketwire - Aug. 14, 2009) - NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS…